Harbour BioMed Welcomes Dr. Lloyd Klickstein as New Immunology Advisor
Harbour BioMed, a prominent global biopharmaceutical company, has taken a significant step forward by appointing Dr. Lloyd Klickstein as its Scientific Advisor for Immunology. This strategic addition is expected to bolster the company's efforts in developing innovative antibody therapeutics across various medical fields, particularly immunology. Dr. Klickstein brings with him an impressive portfolio of experience in biopharmaceutical innovation, translational research, and clinical medicine, making him a valuable asset to Harbour BioMed's team.
Dr. Klickstein's career spans over two decades where he has become a renowned figure in the fields of rheumatology and immunology. Currently serving as the CEO of Koslapp Therapeutics, he has held several key positions, co-founding Versanis Bio, which was later acquired by Eli Lilly and Company. His previous roles included Chief Innovation Officer for Adicet Bio and Chief Scientific Officer at resTORbio. During his extensive tenure at Novartis, Dr. Klickstein led the New Indications Discovery Unit, focusing on the identification of therapeutic targets, a skillset that aligns with Harbour BioMed's objectives.
The company's founder and CEO, Dr. Jingsong Wang, expressed enthusiasm over Dr. Klickstein's arrival, stating that his extensive clinical expertise in both fields will be instrumental in enhancing their immunology pipeline. Given Dr. Klickstein's distinguished record in validating novel therapeutic targets and advancing treatments from discovery through clinical development, Harbour BioMed aims to accelerate its antibody therapeutic programs, especially those addressing immunological diseases. The collaboration with Dr. Klickstein is anticipated to unlock new therapeutic opportunities, potentially transforming patient care in the field of immunology.
Expressing his excitement about joining Harbour BioMed, Dr. Klickstein emphasized the uniqueness of the company's proprietary antibody discovery platforms, which are designed to tackle significant unmet needs in immunological diseases. His vision includes not just advancing existing programs but also pioneering innovative therapies that will provide patients with new hope.
Harbour BioMed has positioned itself as a forward-thinking biopharmaceutical entity focused on the discovery and development of groundbreaking antibody therapeutics. The company’s portfolio is strengthened by its proprietary technologies such as Harbour Mice®, which generates fully human monoclonal antibodies, and more recently, the launch of an AI-powered generative model to enhance their therapeutic development process.
The integration of a single B-cell cloning platform with advanced technologies exemplifies the efficient and robust antibody discovery engine that Harbour BioMed has established. As the company embarks on this promising chapter with Dr. Klickstein’s leadership, industry observers and stakeholders are keenly watching how these advancements will influence the landscape of antibody therapeutics and patient treatment protocols worldwide.
With the commitment to innovation and excellence in biopharmaceutical research, Harbour BioMed is set to lead the way in addressing complex health challenges, particularly in immunology. Observers within the field are optimistic that Dr. Klickstein’s guidance will propel the company’s research into new territories, ultimately benefiting patients suffering from immunological ailments.
Dr. Klickstein's career spans over two decades where he has become a renowned figure in the fields of rheumatology and immunology. Currently serving as the CEO of Koslapp Therapeutics, he has held several key positions, co-founding Versanis Bio, which was later acquired by Eli Lilly and Company. His previous roles included Chief Innovation Officer for Adicet Bio and Chief Scientific Officer at resTORbio. During his extensive tenure at Novartis, Dr. Klickstein led the New Indications Discovery Unit, focusing on the identification of therapeutic targets, a skillset that aligns with Harbour BioMed's objectives.
The company's founder and CEO, Dr. Jingsong Wang, expressed enthusiasm over Dr. Klickstein's arrival, stating that his extensive clinical expertise in both fields will be instrumental in enhancing their immunology pipeline. Given Dr. Klickstein's distinguished record in validating novel therapeutic targets and advancing treatments from discovery through clinical development, Harbour BioMed aims to accelerate its antibody therapeutic programs, especially those addressing immunological diseases. The collaboration with Dr. Klickstein is anticipated to unlock new therapeutic opportunities, potentially transforming patient care in the field of immunology.
Expressing his excitement about joining Harbour BioMed, Dr. Klickstein emphasized the uniqueness of the company's proprietary antibody discovery platforms, which are designed to tackle significant unmet needs in immunological diseases. His vision includes not just advancing existing programs but also pioneering innovative therapies that will provide patients with new hope.
Harbour BioMed has positioned itself as a forward-thinking biopharmaceutical entity focused on the discovery and development of groundbreaking antibody therapeutics. The company’s portfolio is strengthened by its proprietary technologies such as Harbour Mice®, which generates fully human monoclonal antibodies, and more recently, the launch of an AI-powered generative model to enhance their therapeutic development process.
The integration of a single B-cell cloning platform with advanced technologies exemplifies the efficient and robust antibody discovery engine that Harbour BioMed has established. As the company embarks on this promising chapter with Dr. Klickstein’s leadership, industry observers and stakeholders are keenly watching how these advancements will influence the landscape of antibody therapeutics and patient treatment protocols worldwide.
With the commitment to innovation and excellence in biopharmaceutical research, Harbour BioMed is set to lead the way in addressing complex health challenges, particularly in immunology. Observers within the field are optimistic that Dr. Klickstein’s guidance will propel the company’s research into new territories, ultimately benefiting patients suffering from immunological ailments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.